Thromb Haemost 1993; 69(04): 339-343
DOI: 10.1055/s-0038-1651609
Original Article
Coagulation
Schattauer GmbH Stuttgart

The Pharmacokinetics of LMW Dermatan Sulphate: Long-Term Persistence of Intact Material

Joan Dawes
The Heart Research Institute, Sydney, Australia
› Author Affiliations
Further Information

Publication History

Received 28 April 1992

Accepted after revision 01 December 1992

Publication Date:
05 July 2018 (online)

Summary

An iodinated derivative of the low molecular weight dermatan sulphate Desmin 370 was administered to rats by intravenous, subcutaneous and intramuscular routes in conjunction with unlabelled Desmin 370. Following intravenous injection radiolabel was cleared from the plasma according to a tri-exponential function with elimination half-lives of 45 min and 13 h; there was a high concentration in tissues, particularly the kidney, compared with plasma. The apparent bioavailability following s. c. injection was 52-65%, but 84-100% after i. m. administration. Undegraded as well as desulphated molecules were identified in plasma, and intact 125I-Desmin 370 comprised > 85% of the radiolabel in urine 48 h post-injection. Thus intact Desmin 370 persists for a long period after a single injection. The pharmacological significance of these findings, however, remainsto be determined.

 
  • References

  • 1 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
  • 2 Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA. Heparin sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-747
  • 3 Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
  • 4 Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987; 17: 329-335
  • 5 Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemostas 1989; 61: 7-9
  • 6 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. The effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 1989; 556: 304-312
  • 7 Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis. Evidence for an anticoagulant-independent mechanism. Thromb Haemostas 1993; 69: 147-151
  • 8 Sié P, Fernandez F, Caranobe C, Gabaig AM, Boneu B. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate. Thromb Res 1982; 35: 231-236
  • 9 Fernandez F, van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-317
  • 10 Dawes J, Hodson BA, MacGregor IR, Pepper DS, Prowse CV. Pharmacokinetics and biological activities of dermatan sulphate (Mediolanum MF701) in healthy human volunteers. Ann NY Acad Sci 1989; 556: 292-303
  • 11 Dol F, Houin G, Rostin M, Montastruc JL, Dupouy F, Gianese F, Sié P, Boneu B. Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. Blood 1989; 74: 1577-1582
  • 12 Dawes J, McLaren M, Forbes C, Belch JJF, Lane DA, Bray B, McEwen J, Houin G, Gianese F. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers. Br J Clin Pharmacol 1991; 32: 361-366
  • 13 Dawes J, Prowse CV, Pepper DS. Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res 1986; 44: 683-693
  • 14 Dol F, Petitou M, Lormeau JC, Choay J, Caranobe C, Sié P, Saivin S, Houin G, Boneu B. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate. J Lab Clin Med 1990; 115: 43-51
  • 15 European patent no. 221977. Trough Chem Abstr 1990; 107: 78204
  • 16 Dawes J, Pepper DS. Catabolism of low dose heparin in man. Thromb Res 1979; 14: 845-860
  • 17 Greenwood FC, Hunter WM, Glover JS. The preparation of 311I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 14: 114-123
  • 18 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
  • 19 Dawes J, Prowse CV, Pepper DS. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine. Thromb Haemostas 1985; 54: 630-634
  • 20 Dawes J, Hodson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulphate administered to man – studies using a radioiodinated derivative. Thromb Haemostas 1989; 62: 945-949
  • 21 Boneu B, Buchanan MR, Caranobe C, Gabaig AM, Dupouy D, Sié P, Hirsh J. The disappearance of a low molecular weight heparin fraction (CY216) differs from standard heparin in rabbits. Thromb Res 1987; 46: 845-853
  • 22 Bergonzini GL, Bianchini P, Hoppensteadt D, Parma B, Osima B, Walenga JM, Fareed J. Pharmacokinetics of native and low molecular weight dermatans: preliminary studies in rats and primates. Semin Thromb Hemostas 1991; 17 (Suppl. 02) 235-239